2024-10-24
Uppsala, Sweden – October 23, 2024 – Navinci’s Board of Directors is pleased to announce the appointment of Jenny Sundqvist as the new Chief Executive Officer, effective December 1, 2024. Jenny Sundqvist succeeds Robert Gunnarsson, who stepped down earlier this year.
“As announced, the Board has been committed to finding the right leader to drive Navinci’s next phase of growth. We are thrilled to welcome Jenny Sundqvist, whose experience and strategic vision align perfectly with our ambitions. Navinci is poised to enter an exciting phase of innovation and growth under Jenny’s leadership as it advances its mission to reshape protein analysis.” said Eva Pisa, Chair of the Board. “We would also like to extend our sincere gratitude to Agata Zieba-Wicher, Chief Product & Science Officer, for her exceptional leadership and dedication during this transition period.”
With more than 20 years of experience spanning big pharma and biotech, Jenny brings deep expertise in pharmaceutical development and medical devices. Her career encompasses key roles across multiple therapeutic areas, including renal, respiratory, oncology, and immunological diseases. Jenny’s broad skill set includes commercial strategy, business development, portfolio management, and strategic planning.
Most recently, Jenny served as CEO of InDex Pharmaceuticals, where she successfully steered the company through a complex reverse merger with one of Sweden’s leading life science investment firms.
“I am thrilled to join Navinci and excited to contribute to the company’s journey at such a pivotal time,” said Jenny Sundqvist. “Navinci operates in the rapidly evolving field of protein analysis, with extraordinary potential for impact. I look forward to collaborating with the talented team here to unlock new opportunities and help drive the company’s future success.”
For additional information, please contact:
Eva K Pisa, Chair Board of Directors
Telephone: +41-79-598 2185
Email: eva.pisa@pimedconsulting.com